Ronald DePinho

Ronald A. DePinho was the founder of Karyopharm Therapeutics, Inc. founded in 2008, serving as Director from 2009 to 2012.
Dr. DePinho was the founder of Metamark Genetics, Inc. founded in 2007, serving as Director.
Dr. DePinho was the founder of Dana-Farber Cancer Institute, Inc. founded in 1998, serving as Member from 1998 to 2009.
Dr. DePinho was the founder of AVEO Pharmaceuticals, Inc. founded in 2001, serving as Director from 2010 to 2012.
Dr. DePinho was the founder of Tvardi Therapeutics, Inc. (Old) founded in 2017, serving as Chairman.
Dr. DePinho is the founder of Asylia Therapeutics, Inc. founded in 2019, serving as Co-Chairman since 2019.
Dr. DePinho is also the founder of Nirogy Therapeutics, Inc.,Sporos Bioventures LLC,Stellanova Therapeutics, Inc...
Dr. DePinho is Chairman of The NCI Mouse Models of Human Cancers Consortium.
Dr. DePinho is Director of Greater Houston Partnership Inc. Dr. DePinho is Director of BioHouston, Inc. Dr. DePinho is Member of National Cancer Institute.
Dr. DePinho is Member of American Academy of Arts & Sciences.
Dr. DePinho is Member of National Academy of Medicine (United States).
Former positions include Director at American Association for Cancer Research.
Former Director at Technology & Entrepreneurship Center of Houston.
President of The University of Texas M.D.
Anderson Cancer Center from 2011 to 2017.
Member-Medical Oncology & Medicine Department at Harvard Medical School from 1998 to 2009.
Education includes undergraduate degree from Fordham University and doctorate from Albert Einstein College of Medicine, Inc.